195 related articles for article (PubMed ID: 33790099)
1. Effects of Palonosetron on Nausea and Vomiting Induced by Multiple-Day Chemotherapy: A Retrospective Study.
Hamano H; Mitsuhashi C; Suzuki Y; Zamami Y; Tsujinaka K; Okada N; Niimura T; Hayama T; Imai T; Ishida S; Sakamoto K; Goda M; Takechi K; Yagi K; Chuma M; Horinouchi Y; Shinomiya K; Ikeda Y; Kirino Y; Nakamura T; Yanagawa H; Hamada Y; Ishizawa K
Biol Pharm Bull; 2021; 44(4):478-484. PubMed ID: 33790099
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
Gamble M; Carroll E; Wright GC; Glode AE
J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
5. Palonosetron versus Granisetron in Combination with Aprepitant and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy: A Single-Institutional Retrospective Cohort Study.
Miyoshi T; Miyashita H; Matsuo N; Odawara M; Hori M; Hiraki Y; Kawanaka H
Biol Pharm Bull; 2021; 44(10):1413-1418. PubMed ID: 34602550
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
[TBL] [Abstract][Full Text] [Related]
7. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy.
Olver IN; Grimison P; Chatfield M; Stockler MR; Toner GC; Gebski V; Harrup R; Underhill C; Kichenadasse G; Singhal N; Davis ID; Boland A; McDonald A; Thomson D;
Support Care Cancer; 2013 Jun; 21(6):1561-8. PubMed ID: 23274926
[TBL] [Abstract][Full Text] [Related]
8. Palonosetron on Days 1 and 5
Shimura Y; Izumi K; Itai S; Iwamoto H; Yaegashi H; Suga Y; Shimada T; Mizokami A; Sai Y
In Vivo; 2019; 33(2):643-647. PubMed ID: 30804153
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
Suzuki K; Yamanaka T; Hashimoto H; Shimada Y; Arata K; Matsui R; Goto K; Takiguchi T; Ohyanagi F; Kogure Y; Nogami N; Nakao M; Takeda K; Azuma K; Nagase S; Hayashi T; Fujiwara K; Shimada T; Seki N; Yamamoto N
Ann Oncol; 2016 Aug; 27(8):1601-6. PubMed ID: 27358385
[TBL] [Abstract][Full Text] [Related]
10. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
[TBL] [Abstract][Full Text] [Related]
11. A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
Sugimori Y; Ota T; Ujihira T; Ishiguro T; Ogishima D
J Obstet Gynaecol Res; 2017 Sep; 43(9):1454-1459. PubMed ID: 28952201
[TBL] [Abstract][Full Text] [Related]
12. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
13. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
Fujiwara S; Terai Y; Tsunetoh S; Sasaki H; Kanemura M; Ohmichi M
J Gynecol Oncol; 2015 Oct; 26(4):311-9. PubMed ID: 26197776
[TBL] [Abstract][Full Text] [Related]
14. Effects of 5-HT
Goda M; Kanda M; Yoshioka T; Yoshida A; Murai Y; Zamami Y; Aizawa F; Niimura T; Hamano H; Okada N; Yagi K; Chuma M; Izawa-Ishizawa Y; Ishizawa K
Clin Transl Sci; 2021 Sep; 14(5):1906-1916. PubMed ID: 33982438
[TBL] [Abstract][Full Text] [Related]
15. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
16. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.
Hsu YC; Chen CY; Tam KW; Hsu CY
Eur J Clin Pharmacol; 2021 Nov; 77(11):1597-1609. PubMed ID: 33993343
[TBL] [Abstract][Full Text] [Related]
18. Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron.
Coluzzi F; Mattia C
Future Oncol; 2016 Aug; 12(16):1865-76. PubMed ID: 27184113
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of antiemesis effects of granisetron, aprepitant and dexamethasone to palonosetron, aprepitant and dexamethasone in treatment of high-emetic risk chemotherapy-induced nausea and vomiting - a retrospective study for efficacy and safety in a single institute].
Osawa H; Goto H; Myojo T
Gan To Kagaku Ryoho; 2013 May; 40(5):617-21. PubMed ID: 23863585
[TBL] [Abstract][Full Text] [Related]
20. Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy.
Uchida M; Nakamura T; Makihara Y; Suetsugu K; Ikesue H; Mori Y; Kato K; Shiratsuchi M; Hosohata K; Miyamoto T; Akashi K
Pharmazie; 2018 May; 73(5):304-308. PubMed ID: 29724299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
